ARTICLE | Clinical News
Theravance secures U.S. approval for Yupelri in COPD
November 16, 2018 3:52 PM UTC
Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a maintenance treatment of chronic obstructive pulmonary disease. Yupelri marks the first once-daily nebulized bronchodilator to receive U.S. approval for the indication, the companies said.
Theravance expects to launch Yupelri by year end. It declined to disclose the wholesale acquisition cost (WAC)...